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Abstract  20 
Objectives 21 
 This study assessed the impact of discordant empirical antibiotic therapy (ET) on the 22 
outcome of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia 23 
coli (ESBL-EC).  24 
Methods 25 
 The clinical features and outcome for a cohort of patients hospitalized with ESBL-EC 26 
bacteremia between 2007 and 2008 were retrospectively reviewed. The effect of different 27 
antimicrobial regimens on patient outcomes was analyzed. 28 
Results 29 
ESBL-EC accounted for 24.2% (207/857) of E. coli bacteremia cases. Urinary tract 30 
(43.6%) was the most common source of infection, followed by the hepatobiliary tract 31 
(23.0%). Discordant ET was given to 51.9% patients. Admission to the intensive care unit 32 
was associated with the use of carbapenem as ET (p<0.001). Univariate analysis revealed no 33 
significant differences in the 30-day mortality rates between patients receiving concordant 34 
and discordant ET (21.9% vs 19.8%, p=0.732); carbapenem and non-carbapenem ET (29.8% 35 
vs 19.1%, p=0.118); beta-lactam-beta-lactam-inhibitor combinations (BLBLIs) and non-36 
BLBLIs ET (20.3% vs 22.3%, p=0.734); and cephalosporin and non-cephalosporin ET 37 
(18.6% vs 23.1%, p=0.639). The findings were confirmed by multivariate analysis. 38 
Conclusions 39 
 Despite a high proportion of discordant ET, ESBL production had little effect on 30-40 
day mortality. Whether the observation would be applied to different ESBL types is unknown 41 
and warrants further study. 42 
 43 
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Introduction 45 
 In the last five to ten years, the incidence of infections caused by Enterobacteriaceae 46 
producing extended-spectrum -lactamase (ESBL) has increased rapidly and was mainly 47 
attributed to the successful distribution of CTX-M enzymes among Escherichia coli causing 48 
urinary tract and bacteremic infections 1-3. A particularly challenging issue is that CTX-M-49 
producers are increasingly recovered from patients with community-onset infections, 50 
especially those with minimal or absent healthcare risks 4. In Hong Kong, China, we have 51 
previously shown that the CTX-M enzymes are emerging 5-7. Among female outpatients with 52 
urinary tract infections, the ESBL prevalence was 6.6% in 2004 and 10% in 2005 6. All 53 
ESBL-producers were found to carry CTX-M type -lactamases 6.  For bacteremia, the ESBL 54 
rate for both community onset and hospital onset episodes had increased from 8.9% and 55 
20.3% in 2000 to 25.5% and 43.5% in 2010, respectively 8. Consequently, there is a need to 56 
assess how antimicrobial strategies should be modified to minimize the impact of 57 
antimicrobial resistance on patient care. 58 
  59 
 As the majority of ESBL-producing E. coli (ESBL-EC) remains susceptible to the 60 
carbapenems, this class of antibiotics is widely accepted as the agents of choice in treating 61 
patients with serious or bacteremic infections caused by such organisms. However, whether 62 
or not other in vitro active agents such as amoxicillin-clavulanate, piperacillin-tazobactam 63 
and fluoroquinolones can be administered for treating bacteremia remains controversial 9,10. 64 
Furthermore, there is debate on whether the third generation cephalosporins are effective 65 
against low-MIC ESBL-producers 11. While some studies have demonstrated that 66 
inappropriate initial therapy is associated with excess mortality in infections caused by 67 
ESBL-EC 12, 13, others have not found such an association, especially in low risk bacteremia 68 
and when therapy involves agents with some in vitro activity against the infecting ESBL-69 
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producers 14. Therefore, the present study was conducted to describe the impact of ESBL 70 
production and inappropriate empirical therapy on bacteremia caused by ESBL-producing E. 71 
coli.  72 
73 
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Methods 74 
Setting and patient description 75 
 This study was performed in Queen Mary Hospital, which is a university-affiliated 76 
teaching hospital consisting of 1650 beds. As a general recommendation in our hospital, 77 
cefuroxime or amoxicillin-clauvanate are given to patients with mild bacterial infections, 78 
while piperacillin-tazobactam or carbapenem are reserved for patients with moderate or 79 
severe infections as empirical treatment 15. Adult patients aged 18 years or above with 80 
bacteremia due to E. coli bacteremia from January 2007 to December 2008 were identified 81 
with the laboratory information system. Each patient was recruited only once. For patients 82 
with more than one episodes of bacteremia, the first episodes were used in the analysis. 83 
Clinical information of patients infected with ESBL-producing strains was retrieved from the 84 
Clinical Management System. Patients were excluded if clinical records were not accessible 85 
for review or antibiotics were not given before death. This study has been approved by the 86 
Institutional Review Board of the University of Hong Kong/ Hospital Authority Hong Kong 87 
West Cluster.  88 
 89 
Bacterial identification and antimicrobial susceptibility testing 90 
 The BACTEC 9240 blood culture system (Becton Dickinson, MD, USA) was used for 91 
processing of blood specimens. Bacterial isolates were identified using the VITEK GNI 92 
system (bioMérieux Vitek Inc., Hazelwood, MO, USA). Antibiotics susceptibility testing was 93 
performed using the Kirby–Bauer disk diffusion method and interpreted according the 94 
Clinical and Laboratory Standards Institute interpretative criteria 16.  95 
 96 
Definitions 97 
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 Healthcare risk factors included hospital onset (first positive blood culture collected 98 
on ≥2 days after admission), prior hospitalization within 1 year before the positive blood 99 
culture and residency in residential care home for the elderly (RCHE). Community-associated 100 
infection was defined as infection in a patient who did not have any healthcare risk factors, 101 
while hospital-associated infection was infection in those who had any healthcare risk factors. 102 
Charlson comorbidity index was used in measuring comorbidity using ICD-9 coding and 103 
verified by review of records17. Empirical antibiotic therapy (ET) was defined as antibiotics 104 
given before the culture result was reported, whereas known pathogen therapy (KPT) was 105 
defined as antibiotics given after culture result was reported. Concordant therapy was defined 106 
by the use of carbapenems, beta-lactam-beta-lactam-inhibitor combinations (BLBLIs) or 107 
fluoroquinolones to which the isolated strain was susceptible. Discordant therapy was defined 108 
by in-vitro resistance to the given antibiotics. The use of third-generation cephalosporins was 109 
considered to be discordant irrespective of in vitro results 11.  110 
 111 
Statistical analysis 112 
 Statistical analysis was performed using SPSS software, version 17.0 for Windows 113 
(SPSS). 2 test was used for comparison of categorical variables. Univariate and multivariate 114 
analyses were used to assess factors that affect patient outcome. The following parameters 115 
were included in the multivariate analysis: age, sex, comorbidities, source of infection and ET. 116 
For the calculation of the length of stay, patients in which length of stay cannot be 117 
determined were excluded. A P-value of <0.05 was considered to be statistically significant.  118 
 119 
120 
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Results 121 
During the 24-month study period, there were a total of 857 adult patients with a 122 
positive blood culture for E. coli. Of these, 207 (24.2%) patients had ESBL-EC bacteremia. 123 
Two patients were excluded because the clinical records were not available for review and 124 
one patient was excluded because antimicrobial was not given before death. Therefore, 204 125 
patients were included in this study (Table 1). Overall, 8.3% (17/204) and 91.7% (187/204) 126 
of the patients were classified as having community-associated and hospital-associated 127 
infections respectively. Among the hospital-associated infections, 32.1% (60/187) were 128 
classified as hospital onset, 38.5% (72/187) were RCHE residents and 89.8% (168/187) had 129 
prior hospitalization within 1 year. More than two-thirds of the patients were aged 65 years or 130 
above. At the time of blood culture collection, more than 50% of patients were located in the 131 
medical ward. Urinary tract (43.6%) was the most common source of infection, followed by 132 
the hepatobiliary tract (23.0%).  133 
 134 
 Table 2 shows the result of the susceptibility testing. All strains were susceptible to 135 
imipenem. Over 90% of the strains were susceptible to piperacillin-tazobactam or amikacin.  136 
 137 
 The use of antibiotics is illustrated in Figure 1. There was no significant difference in 138 
the Charlson comorbidity score between patients with different ET regimens. Patients who 139 
required admission to the intensive care unit were more likely to receive carbapenem than 140 
those who did not (70.0% [14/20] vs 17.9% [33/184], p<0.001). Concordant ET was given to 141 
98 (48%) patients, including 22 patients who were concurrently treated with more than one in 142 
vitro active antibiotics. Discordant ET was given to 106 (51.9%) patients. The mean duration 143 
of discordant therapy was 2.5 days (standard deviation: 0.9 days). Nineteen patients (9.3%, 144 
including 10 patients on concordant and 9 patients on discordant therapy) died before 145 
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antibiotic susceptibility results were reported. Out of the 185 patients with KPT, 154 (83.2%) 146 
patients received concordant KPT. Among patients who did not receive carbapenem as ET, 147 
91 (63.6%) received carbapenem as KPT. For the 52 patients who did not receive 148 
carbapenem as KPT, 21 received BLBLIs (11 amoxicillin-clavulanate, 8 piperacillin-149 
tazobactam, 1 ticarcillin-clavulanate), 19 received cefuroxime, 6 received fluoroquinolones, 150 
and 3 received other antibiotics (2 nitrofurantoin, 1 cotrimoxazole).  151 
 152 
 Overall, the median length of stay was 17 days (interquartile range 9-33 days). The 153 
length of stay could not be determined for a patient who had been transferred to another 154 
hospital, and another patient who has not been discharged from the hospital at the time of 155 
writing. Twenty (9.8%) patients required admission to the intensive care unit, in whom 14 156 
(70%) received carbapenem ET. Forty-four (21.6%) patients died within 30 days of blood 157 
culture collection. Patients without healthcare risk factors had a significantly lower 30-day 158 
mortality rate than those with healthcare risk factors (0% [0/17] vs 23.5% [44/187], p=0.024). 159 
There was no statistically significant differences in the 30-day mortality rate between 160 
different ET regimens: concordant vs discordant (23.5% [23/98] vs 19.8% [21/106], 161 
p=0.526); carbapenem (Group 1) vs non-carbapenem (Group 2) (29.8% [14/47] vs 19.1% 162 
[30/157], p=0.118) (Figure 1); BLBLIs vs non-BLBLIs (20.3% [15/74] vs 22.3% [29/130], 163 
p=0.734); cephalosporin vs  non-cephalosporin (18.6% [14/71] vs 22.6% [30/133], p=0.639); 164 
fluoroquinolone (group 2b) vs non-fluoroquinolone (8.3% [1/12] vs 22.4% [43/192], 165 
p=0.251]. When susceptibility results for the BLBLIs were interpreted as found, the 30 day 166 
mortality rates for patients who received concordant and discordant BLBLI were 19.1% 167 
(9/47) and 22.2% (6/27), respectively (p=0.752). When all BLBLIs were considered to be 168 
discordant irrespective of the in vitro result, the mortality rate for concordant and discordant 169 
ET became 27.5% (14/51) and 19.6% (30/153), respectively (p=0.238). There was no 170 
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statistically significant difference in the length of stay between different ET regimens. 171 
Discordant ET was not associated with higher 30-day mortality or longer length of stay in the 172 
multivariate analysis. Among patients who did not receive carbapenem as ET (group 2), the 173 
30-day mortality rates were not significantly different between patients who received 174 
carbapenem as KPT and those who did not (11.0% [10/91] vs 11.5% [6/52], p=1.000); 175 
between patients receiving BLBLIs and non-BLBLIs (14.3% [3/21] vs 10.7% [13/122], 176 
p=0.626); and between patients who received cephalosporins and those who received other 177 
antibiotics (15.8% [3/19] vs 10.5% [13/124], p=0.494). Taken together, there was no clear 178 
association between the choice of antimicrobial and outcome. 179 
 180 
181 
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Discussion 182 
 Our study showed that a high proportion of patients with ESBL-EC bacteremia 183 
received initial therapy which was considered to be inappropriate because many of them 184 
involved agents with little in-vitro activity or uncertain efficacy against the infecting 185 
organisms. In most patients, such “inappropriate” (i.e. discordant) therapy lasted two to three 186 
days. Our findings showed that this had little effect on patient mortality and the length of stay 187 
in hospital. In addition to the relatively short duration of inappropriate therapy, there were 188 
other possible explanations for our findings. Firstly, the “inappropriate” antibiotics might 189 
have some activity in vivo. Cephalosporins have been associated with treatment failure, but 190 
they might be effective for infections caused by organisms with low-MIC ESBL-producers 18. 191 
BLBLIs, particularly piperacillin-tazobactam, have been shown to be non-inferior to 192 
carbapenems in a recent post-hoc analysis of 6 prospective cohorts of ESBL-EC bacteremia 9. 193 
Secondly, the site of infection is an important determinant of patients’ outcome. Almost half 194 
of the patients in our cohort had urinary tract infection. Bacteremia due to urinary tract 195 
infection has been considered to be of low risk 19. The second most common source was the 196 
hepatobiliary tract. Many of our patients had cholangitis which required biliary drainage. In 197 
these situations, early drainage is more important than antibiotics in determining patients’ 198 
outcome 20, 21. Thirdly, the severity of disease can affect outcome. In general, patients with 199 
severe disease are more likely to receive antibiotics with wider spectrum or combinations of 200 
antibiotics, thereby more likely to be in vitro active. In our cohort, 70% of patients in 201 
intensive care unit received carbapenem as ET. Finally, the type of ESBL enzyme may affect 202 
outcome. In the present study, CTX-M-9 group enzymes predominated among the ESBL-EC 203 
isolates which are often susceptible to BLBLI and ceftazidime in vitro 3. By comparison, 204 
ESBL-EC producers in the UK were often found to have both CTX-M-15 and OXA-type 205 
enzymes and were resistant to BLBLIs and ceftazidime 22.  206 
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 207 
 The prevalence of ESBL-EC strains among E. coli bacteremia (24.2%) in our study 208 
was higher than those reported in other studies conducted during the same period 22, 23. In our 209 
previous study, the incidence density of ESBL-EC bacteremia has increased from 8.6 per 210 
100,000 patient-days in year 2000-2005 to 16.9 per 100,000 patient-days in year 2006-2010 8. 211 
Previously identified risk factors for ESBL-producers included healthcare associations such 212 
as RCHE residency and hospital onset bacteremia, recent use of antibiotics, comorbidities, 213 
presence of gastrostomy tubes or urinary catheters, and urinary tract infections 24-26. The 214 
baseline characteristics of our study cohort concur with these known risk factors. We have 215 
also found that 8.3% of patients with ESBL-EC bacteremia were community associated. The 216 
prevalence of community-acquired infections has been increasing, and one study in India 217 
showed that up to 46% of Enterobacteriaceae strains from outpatients were ESBL-producer 218 
27. The increase in community-acquired ESBL-EC infection parallels with the increasing 219 
carriage of ESBL-EC in the community. In Hong Kong, stool carriage of ESBL-producing 220 
organisms was found in 43.5% in the children who were admitted for respiratory tract 221 
infection and their household members 28. The rate of ESBL-producers in urine collected 222 
from women in the community now exceeds >5% 6, 29. It has been postulated that an increase 223 
in ESBL-EC in the community is due to the high rate of antibiotic resistance in food animals 224 
30. In our locality, there is a high fecal carriage rate of ESBL-EC in food animals, exceeding 225 
60% in live pigs and chickens 5. Since ESBL-EC bacteremia results in high mortality as 226 
shown in the current study (21.6%), controlling the incidence and spread of ESBL-EC in the 227 
community would be very important. 228 
 229 
 Over 90% of our isolates were susceptible to piperacillin-tazobactam. The 230 
piperacillin-tazobactam susceptible rate in our cohort was higher than that reported in other 231 
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studies 31, 32. To a certain extent, such variations in susceptibility reflect differences in the 232 
major clonal types and ESBL enzymes. In Hong Kong, the CTX-M-9 group and CTX-M-14 233 
allele were the predominat ESBL type 3. Among the patients in the present study, the 234 
sequence type (ST) was determined for the isolates from 116 randomly selected patients, 235 
among which 30 patients (25.9%) had infection by E. coli belonging to ST131. The 236 
remaining isolates included 5 ST69, 3 ST12, 3 ST68 and 75 singletons 3. In our study, we 237 
have also found a low susceptibility rate to levofloxacin. This is of particular concern, as 238 
patients with contraindications to receiving beta-lactams, such as allergic reactions, are often 239 
given fluoroquinolone as ET. Our results stressed the importance of adding amikacin as ET if 240 
patients are suffering from severe infections.  241 
 242 
 There are several limitations in this study. Firstly, retrospective analysis of factors 243 
affecting patients’ outcome is often affected by confounding factors. Previous studies have 244 
used case-control studies to adjust for confounding factors, but adjustment for disease 245 
severity is difficult. Secondly, as the attending clinicians adjusted the antimicrobial regimen 246 
according to their clinical judgment, a patient could have received several classes of 247 
antibiotics as empirical therapy. Therefore, a prospective randomized controlled study would 248 
be needed to assess the effect of different therapies. Thirdly, we were not able to analyze the 249 
effect of third generation cephalosporin as only 4% of the patients received them as ET.   250 
 251 
 The result of this study highlights the therapeutic challenges faced by clinicians in 252 
areas where ESBL is highly prevalent. We submit that prudent choice of antimicrobial agents 253 
according to patient characteristics and disease severity should continue to be practiced 15. 254 
Rapid determination of the identity and antibiotics susceptibility of the organisms is crucial 255 
for early optimization of antibiotics, especially for patients with severe infections. Currently 256 
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available methods for rapid detection of resistant organisms include direct antibiotics 257 
susceptibility testing 33, molecular techniques detecting resistance genes 34 and matrix-258 
assisted laser desorption ionization-time of flight mass spectrometry detecting -lactamases 35. 259 
Optimization of the treatment strategy of infections caused by ESBL-producers is urgently 260 
needed, since the over-reliance on carbapenem will promote the emergence of carbapenem-261 
resistant organisms 36. 262 
 263 
 264 
265 
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Figure legend 421 
Figure 1. Antimicrobial therapy and outcome in the 204 patients with ESBL-producing 422 
Escherichia coli bacteremia.  423 
 204a
Group 1
With carbapenem
n=47
14 /47 died
Group 2 
No carbapenem
n=157
Group 2ab
Other beta‐lactam
n=145 
Died before results reported
n=14
KPT = carbapenem
n=85
9/85 died 
KPT = others
n=46
6/46 died
Group 2bc
Fluoroquinolone
n=12
KPT
Carbapenem n=6 
Other n=6
1/12 died
a Twenty-three patients had polymicrobial bacteremia, in which Klebsiella pneumoniae was the most common co-isolate (43.5%, 
10/23). Other organisms include Bacillus species (4 patients), Proteus mirabilis (3 patients), Pseudomonas aeruginosa (2 patients), 
Enterococcus faecalis (2 patients), Bacteroides/ non-pigmented Prevotella group (1 patient), Clostridium species (1 patient), 
Fusobacterium species (1 patient), Peptostreptococcus species (1 patient), and Coagulase negative Staphylococcus (1 patient). 
b BLBLI: 74 patients; first or second generation cephalosporin: 63 patients; third generation cephalosporin (cefotaxime, ceftriaxone, 
cefoperazone-sulbactam): 8 patients. For patients with BLBLI, 47 (63.5%) were concordant and 27 (36.5%) were discordant 
c 4 were concordant; 8 were discordant 
